Rick Gonzalez, AbbVie CEO (Pablo Martinez Monsivais/AP Images)
AbbVie braces for 'greater erosion' of Humira franchise in second half of this year
AbbVie execs touted a wave of Rinvoq programs at Cowen’s annual conference on healthcare Tuesday as they brace for a tougher Humira battle in the second half of this year.
Since its first approval in rheumatoid arthritis in 2002, Humira became one of industry’s top sellers ever, adding a wide list of indications from ulcerative colitis to ankylosing spondylitis. The first biosimilar to Humira, Amgen’s Amjevita, launched at the end of January, and AbbVie execs announced on the last quarterly call that they expect a 37% drop in Humira sales this year.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters